Maraviroc , a chemokine co-receptor type @ ( CCR@ ) antagonist , has demonstrated comparable efficacy and safety to efavirenz , each in combination with zidovudine/lamivudine , over @ weeks in the Maraviroc vs. Efavirenz Regimens as Initial Therapy ( MERIT ) study .